NEW YORK: Drugmaker Pfizer is expanding its late-stage COVID-19 vaccine trial to include children as young as 12, in a bid to better understand the safety and efficacy of the vaccine across more age groups. The company said on Monday (Oct 12) that it had received permission from the Food and Drug …
